Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Jan 2019
Historique:
received: 09 07 2018
revised: 08 11 2018
accepted: 09 11 2018
pubmed: 26 11 2018
medline: 8 2 2019
entrez: 26 11 2018
Statut: ppublish

Résumé

Second- and third-generation inhibitors of EGFR possess an acrylamide group which alkylates Cys797, allowing to overcome resistance due to insurgence of T790M mutation. Less reactive warheads, yet capable to bind the target cysteine, may be useful to design newer and safer inhibitors. In the present work, we synthesized a 2-chloro-N-(4-(phenylamino)quinazolin-6-yl)acetamide (8) derivative as a prototype of EGFR inhibitor potentially able to react with Cys797 by nucleophilic substitution. We then tuned the reactivity of the acetamide fragment by replacing the chlorine leaving group with (hetero)-aromatic thiols or carboxylate esters. Among the synthesized derivatives, the 2-((1H-imidazol-2-yl)thio)acetamide 16, while showing negligible reactivity with cysteine in solution, caused long-lasting inhibition of wild-type EGFR autophosphorylation in A549 cells, resulted able to bind recombinant EGFR L858R/T790M in a time-dependent manner, and inhibited both EGFR autophosphorylation and proliferation in gefitinib-resistant H1975 lung cancer cells (expressing EGFR L858R/T790M mutant) at low micromolar concentration.

Identifiants

pubmed: 30472599
pii: S0223-5234(18)30988-7
doi: 10.1016/j.ejmech.2018.11.029
pii:
doi:

Substances chimiques

Acetamides 0
Antineoplastic Agents 0
Thioacetamide 075T165X8M
acetamide 8XOE1JSO29
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Cysteine K848JZ4886
Gefitinib S65743JHBS

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

507-524

Informations de copyright

Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Auteurs

Riccardo Castelli (R)

Department of Food and Drug, University of Parma, Parma, Italy.

Nicole Bozza (N)

Department of Food and Drug, University of Parma, Parma, Italy.

Andrea Cavazzoni (A)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Mara Bonelli (M)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Federica Vacondio (F)

Department of Food and Drug, University of Parma, Parma, Italy.

Francesca Ferlenghi (F)

Department of Food and Drug, University of Parma, Parma, Italy.

Donatella Callegari (D)

Department of Food and Drug, University of Parma, Parma, Italy.

Claudia Silva (C)

Department of Food and Drug, University of Parma, Parma, Italy.

Silvia Rivara (S)

Department of Food and Drug, University of Parma, Parma, Italy.

Alessio Lodola (A)

Department of Food and Drug, University of Parma, Parma, Italy. Electronic address: alessio.lodola@unipr.it.

Graziana Digiacomo (G)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Claudia Fumarola (C)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Roberta Alfieri (R)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Pier Giorgio Petronini (PG)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Marco Mor (M)

Department of Food and Drug, University of Parma, Parma, Italy. Electronic address: marco.mor@unipr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH